Mirova Takes $324,000 Position in Gilead Sciences, Inc. $GILD

Key Points

• Mirova has invested $324,000 in Gilead Sciences, Inc., acquiring 2,895 shares during the first quarter.
• Several analysts have raised their ratings and price targets on Gilead, with Royal Bank Of Canada and Truist Financial expecting targets of $98.00 and $127.00, respectively, indicating a positive outlook.
• Gilead has declared a quarterly dividend of $0.79, with a payment set for September 29th, which reflects a 2.8% dividend yield.

Mirova acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,895 shares of the biopharmaceutical company's stock, valued at approximately $324,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $25,000. Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $29,000. Colonial Trust Advisors raised its position in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares in the last quarter. Core Alternative Capital raised its position in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares in the last quarter. Finally, IMA Advisory Services Inc. purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $39,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. UBS Group lifted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $115.39.

Gilead Sciences Trading Down 0.7%

Gilead Sciences stock traded down $0.83 during trading hours on Wednesday, reaching $113.92. The stock had a trading volume of 4,663,278 shares, compared to its average volume of 6,572,293. The stock has a market cap of $141.35 billion, a PE ratio of 22.69, a PEG ratio of 0.70 and a beta of 0.33. Gilead Sciences, Inc. has a 52 week low of $77.23 and a 52 week high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a fifty day simple moving average of $112.71 and a 200-day simple moving average of $109.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at $18,977,838.30. This trade represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,339,230 in the last quarter. Insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.